Wegovy weight loss timeline: week-by-week expectations (2026)

The first 4 weeks: appetite suppression starts, scale barely moves

Wegovy starts at 0.25mg weekly for the first 4 weeks. This is intentionally subtherapeutic — it's the titration starting point to build GI tolerance, not the dose at which meaningful weight loss happens. Most patients lose 1-2 pounds total in the first month, sometimes nothing. This is normal.

What you'll notice instead: appetite suppression starts within days. Food cravings reduce, portion sizes you used to finish suddenly feel like too much, and the constant mental food-noise quiets. The scale doesn't reflect this yet because total calorie reduction hasn't yet exceeded baseline metabolic flexibility.

Common week 1-4 side effects: mild nausea, especially in the 24-48 hours after the weekly injection. Constipation. Fatigue. Sulfur burps in some patients. These usually settle within 2-3 weeks at this dose.

Weeks 5-12: dose escalation begins, weight loss accelerates

Standard titration moves to 0.5mg at week 5, 1.0mg at week 9. This is when most patients start seeing meaningful scale change. Typical weight loss by week 12: 4-8 pounds from baseline. Cumulative ~3-5% body weight loss.

Side effects often peak with each dose increase, then settle within 1-2 weeks. If side effects become severe or persistent, your prescriber may extend a dose level (stay at 0.5mg for 8 weeks instead of 4) before escalating further. This is normal clinical practice and doesn't reduce eventual outcomes.

Lifestyle work matters most now. Adequate protein (1.0-1.2g/kg body weight), resistance training 2x weekly minimum, hydration, sleep. The medication suppresses appetite but doesn't choose what you eat — protein quality during weight loss determines whether you lose primarily fat or also significant muscle.

Weeks 13-17: reaching maintenance dose, plateau-resistant zone

Standard titration: 1.7mg at week 13, 2.4mg at week 17. The 2.4mg dose is the FDA-approved maintenance dose for chronic weight management.

Typical weight loss by week 17: 8-15 pounds from baseline. Cumulative ~5-8% body weight loss. The pace of loss is generally fastest in months 3-6, then slowly tapers.

Some patients stay at 1.7mg as their maintenance dose rather than escalating to 2.4mg, particularly if side effects are persistent at the higher dose. Clinical trials show ~80% as much weight loss at 1.7mg vs 2.4mg, so this is a clinically reasonable choice when tolerability is an issue.

Months 5-9: the steady-state loss phase

On maintenance dose (2.4mg or 1.7mg), most patients lose 1-2 pounds per week for months. By month 6, typical cumulative loss is 8-12% of starting body weight. By month 9, 12-15%.

Plateau usually starts around month 9-12 as the body defends its new weight set point. This is biology, not treatment failure. See our separate article on plateau strategies if you hit it.

Body composition matters most here. With adequate protein + resistance training, the loss is mostly fat. Without those, ~25-40% of the loss can be lean mass — which reduces basal metabolic rate and increases regain risk after discontinuation. Don't skimp on protein or strength work just because the scale moves anyway.

Month 12+: long-term maintenance

STEP-1 trial data: mean 14.9% weight loss at 68 weeks (a bit over 15 months). Individual results vary widely: top 10% of responders see 25%+; bottom 10% see <5%. Most patients fall in the 10-20% range.

Long-term sustainability requires staying on the medication. STEP-4 trial showed that patients who continued Wegovy past 68 weeks maintained their losses; those switched to placebo regained ~7% within a year. This is the same as bariatric surgery's recommended lifestyle commitment — long-term treatment for long-term effect.

If you stop Wegovy: weight regain is the expected default unless you've structured a robust maintenance plan with continued lifestyle modification + possibly a maintenance microdose strategy.

When to call your prescriber

You're 4-6 months in at the highest tolerated dose with <5% body weight loss → time to discuss switching to tirzepatide (Zepbound) or escalating diagnostic workup.

Severe GI side effects that don't settle within 2-3 weeks of a dose increase → discuss dose hold or step-down.

Signs of pancreatitis (severe upper abdominal pain radiating to back), gallbladder symptoms (right upper quadrant pain, nausea after fatty meals), or any concerning new symptoms → call immediately.

Unable to eat enough to maintain adequate nutrition (severe early satiety, persistent vomiting) → likely needs dose adjustment.